Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium (99mTc) hynic-octreotide (Radioisotope Centre POLATOM)
- Development stage
- Unknown
- Lead developer
- Radioisotope Centre POLATOM
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Technetium (99mTc) hynic-octreotide (marketed under the brand name Tektrotyd) is a diagnostic radiopharmaceutical used in nuclear medicine for single-photon emission computed tomography (SPECT) imaging. It consists of the somatostatin analog Tyr3-octreotide (TOC) conjugated to the hydrazinonicotinamide (HYNIC) chelator, which is radiolabeled with technetium-99m (99mTc) using ethylenediamine-N,N'-diacetic acid (EDDA) as a co-ligand. The tracer selectively binds to somatostatin receptors (primarily subtype 2, SSTR2, and to a lesser extent SSTR3 and SSTR5) overexpressed on neuroendocrine tumors (NETs) and other SSTR-positive tissues. Upon binding, it undergoes receptor-mediated internalization, allowing for the localization and staging of primary and metastatic neuroendocrine tumors, as well as evaluating patient eligibility for peptide receptor radionuclide therapy (PRRT).
- Brand names
- TectrotydTektrotyd
- Other names
- 99mTc-EDDA/HYNIC-TOC99mTc-EDDA/HYNIC-Tyr3-octreotide99mTc-HYNIC-TOC99mTc-HYNIC-Tyr3-octreotide99mTc-TOC99mTc-Tectrotyd99mTc-Tektrotydtechnetium-99m hydrazinonicotinamide-octreotidetechnetium99m hydrazinonicotinamide-octreotidetechnetium 99m hydrazinonicotinamide-octreotidetechnetium-99m hydrazinonicotinyl-Tyr3-octreotidetechnetium99m hydrazinonicotinyl-Tyr3-octreotidetechnetium 99m hydrazinonicotinyl-Tyr3-octreotide
02
Targets
SSTR2 (Somatostatin receptor type 2)
Beyond the preview
Go deeper on technetium (99mTc) hynic-octreotide (Radioisotope Centre POLATOM).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium (99mTc) hynic-octreotide (Radioisotope Centre POLATOM).